Eprenetapopt Plus Azacitidine in

Authors :: Thomas, Cluzeau
Marie, Sebert
Ramy, Rahmé
Stefania, Cuzzubbo
Jacqueline, Lehmann-Che
Isabelle, Madelaine
Pierre, Peterlin
Blandine, Bève
Habiba, Attalah
Fatiha, Chermat
Elsa, Miekoutima
Odile Beyne, Rauzy
Christian, Recher
Aspasia, Stamatoullas
Lise, Willems
Emmanuel, Raffoux
Céline, Berthon
Bruno, Quesnel
Michael, Loschi
Antoine F, Carpentier
David A, Sallman
Rami, Komrokji
Anouk, Walter-Petrich
Sylvie, Chevret
Lionel, Ades
Pierre, Fenaux
Source :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(14)
Publication Year :: 2021
Abstract: This phase II study assessed the safety and efficacy of eprenetapopt in combination with AZA in untreated high or very high International Prognostic Scoring System-RFifty-twoIn this very high-risk population of

Subjects :: Adult
Aged, 80 and over
Leukemia, Myeloid, Acute
Quinuclidines
Myelodysplastic Syndromes
Antineoplastic Combined Chemotherapy Protocols
Mutation
Azacitidine
Humans
Middle Aged
Tumor Suppressor Protein p53
Aged

ISSN :: 15277755
Volume :: 39
Issue :: 14
Database :: OpenAIRE
Journal :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Accession number :: edsair.pmid..........e5d85532a1474b94a2cca06bf76787f6

Tools